Drug developer Tesaro explores sale

Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.

Shares of the Waltham, Massachusetts-based company rose as much as 44 percent on the news in regular trading.

The company, which has a market capitalization of $1.92 billion, said it does not comment on rumor or speculation.

According to the Bloomberg report , the advisers have begun contacting other potential suitors and the company could opt to remain independent.

Tesaro has received acquisition interest from several drugmakers in the past. In July, reports emerged of a possible buyout of the company by Swiss drugmaker Roche Holding AG.

Tesaro’s lead ovarian cancer drug, Zejula, competes with Clovis Oncology Inc’s Rubraca and AstraZeneca’s Lynparza – all of which belong to a closely watched class of new medicines called PARP inhibitors.

  • Related Posts

    • Pharma
    • August 1, 2025
    • 39 views
    Trump pressures 17 pharma CEOs to cut US drug prices

    WASHINGTON, July 31 (Reuters) – President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas,…

    • Pharma
    • August 1, 2025
    • 39 views
    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25%…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Trump pressures 17 pharma CEOs to cut US drug prices

    Trump pressures 17 pharma CEOs to cut US drug prices

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

    Karnataka issues order to merge Ayush drug dept with State FDA

    Karnataka issues order to merge Ayush drug dept with State FDA

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%

    Orchid Pharma buyback rights to novel antibiotic; stock up 5%